PROCEPT BioRobotics Corporation (PRCT) Current Ratio
- Current ratio · latest quarter: Value 6.55×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.55× | Current assets / current liabilities. $420.29M ÷ $64.20M ≈ 6.55× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 420.29M USD | Assets, Current |
| Current obligations | 64.20M USD | Liabilities, Current |
| Cash and equivalents | 227.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 107.61M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 77.06M USD | Inventory, Net |
| Payables | 15.07M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $420.29M | $64.20M | $227.91M | (m) | $107.61M | $77.06M | $15.07M | (m) | 6.55× |
| 2026-03-31 | $428.03M | $63.64M | $245.64M | (m) | $96.39M | $77.54M | $18.85M | (m) | 6.73× |
| 2025-12-31 | $450.38M | $65.80M | $286.50M | (m) | $83.53M | $70.69M | $17.29M | (m) | 6.85× |
| 2025-09-30 | $454.75M | $53.90M | $294.28M | (m) | $84.50M | $66.72M | $11.12M | (m) | 8.44× |
| 2025-06-30 | $458.07M | $49.73M | $302.72M | (m) | $80.82M | $67.03M | $11.78M | (m) | 9.21× |
| 2025-03-31 | $465.79M | $52.06M | $316.21M | (m) | $79.27M | $62.33M | $14.83M | (m) | 8.95× |
| 2024-12-31 | $481.84M | $53.13M | $333.73M | (m) | $83.50M | $56.17M | $10.03M | (m) | 9.07× |
| 2024-09-30 | $322.98M | $53.65M | $196.76M | (m) | $69.05M | $50.85M | $15.09M | $0.00 | 6.02× |
| 2024-06-30 | $321.89M | $42.84M | $214.09M | (m) | $58.92M | $43.87M | $9.95M | $0.00 | 7.51× |
| 2024-03-31 | $329.19M | $38.65M | $225.58M | (m) | $56.08M | $41.62M | $10.08M | $0.00 | 8.52× |
| 2023-12-31 | $350.57M | $45.93M | $257.22M | (m) | $48.38M | $39.76M | $13.50M | (m) | 7.63× |
| 2023-09-30 | $368.67M | $41.36M | $287.09M | (m) | $34.62M | $42.20M | $13.60M | $0.00 | 8.91× |
| 2023-06-30 | $230.02M | $35.95M | $149.69M | (m) | $33.17M | $42.64M | $10.04M | $0.00 | 6.40× |
| 2023-03-31 | $245.58M | $32.50M | $180.97M | (m) | $20.64M | $38.93M | $10.34M | $0.00 | 7.56× |
| 2022-12-31 | $272.63M | $35.29M | $221.86M | (m) | $15.27M | $28.54M | $9.39M | (m) | 7.73× |
| 2022-09-30 | $288.93M | $27.36M | $249.22M | (m) | $12.84M | $22.36M | $6.33M | $0.00 | 10.56× |
| 2022-06-30 | $298.34M | $18.63M | $269.81M | (m) | $10.89M | $13.78M | $3.34M | $0.00 | 16.01× |
| 2022-03-31 | $307.98M | $14.76M | $284.29M | (m) | $6.99M | $12.63M | $2.63M | $0.00 | 20.87× |
| 2021-12-31 | $326.17M | $16.24M | $304.32M | (m) | $4.46M | $13.15M | $2.03M | (m) | 20.08× |
| 2021-09-30 | $339.47M | $14.18M | $320.48M | (m) | $6.35M | $10.40M | $3.59M | $0.00 | 23.94× |
| 2020-12-31 | $110.26M | $14.53M | $100.13M | (m) | $1.55M | $6.92M | $1.24M | $4.55M | 7.59× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |